CorrespondenceThe COOPERATE trial: a letter of concern
References (3)
Cited by (89)
Hypertensive Chronic Kidney Disease
2018, Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector’s The KidneySequential RAAS Blockade: Is It Worth the Risk?
2014, Advances in Chronic Kidney DiseaseCitation Excerpt :It was suggested that ACE inhibition was incomplete because of conversion of angiotensin I to II by local chymases and because blockade of angiotensin II receptor 1 with ARBs was not complete because other angiotensin II receptors were not affected. An early clinical study in non-diabetic CKD showed interesting results, albeit with no hard endpoints, and it sparked increased interest, but it was later retracted because of suspicion of fraud.17 Nevertheless, a series of studies followed investigating different combinations of RAAS blockade.
The End of the Road for Dual Renin Angiotensin System Blockade in Diabetic Nephropathy: Which Way Now?
2014, Canadian Journal of DiabetesCitation Excerpt :In ONTARGET, 38% of participants had diabetes (20), and the mean ACR was approximately 0.81 mg/mmol (21), well within the normal range. The same year, concerns raised as to the validity of the subsequently retracted Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Non-Diabetic Renal Disease (COOPERATE) study that examined dual RAS blockade in nondiabetic renal disease began to cast a further cloud over the whole field (22,23). Subsequent studies have further doused the flames of using dual RAS blockade as a treatment for diabetic nephropathy.
ALTITUDE trial and dual RAS blockade: The alluring but soft science of the surrogate end point
2013, American Journal of MedicineTreatment of chronic kidney disease
2012, Kidney InternationalCitation Excerpt :One early report of the COOPERATE trial claimed that the combination was superior to the individual drugs.25 However, these results and their analyses have been brought into question and retracted.26,27 These events make any conclusions drawn from the COOPERATE trial invalid.
Combination inhibition of the renin-angiotensin system: Is more better
2011, Kidney International